VSTM•benzinga•
FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer
Summary
FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million funding for future developments.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 8, 2025 by benzinga